Havemeyer Place LP Purchases New Position in Abbott Laboratories $ABT

Havemeyer Place LP purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 6,294 shares of the healthcare product maker’s stock, valued at approximately $789,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Freemont Management S.A. grew its holdings in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab purchased a new stake in Abbott Laboratories in the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans grew its holdings in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Abbott Laboratories in the third quarter worth about $185,640,000. Finally, Net Worth Advisory Group purchased a new stake in Abbott Laboratories in the fourth quarter worth about $1,366,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ABT. Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Oppenheimer cut their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Evercore cut their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Down 0.7%

Shares of NYSE ABT opened at $90.46 on Tuesday. The firm’s 50 day moving average price is $92.52 and its 200-day moving average price is $108.88. The company has a market cap of $157.57 billion, a PE ratio of 25.34, a P/E/G ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.